Sapien 3 Ultra THV outperforms its predecessor, reducing PVL after TAVR procedures

Transcatheter aortic valve replacement (TAVR) with the Sapien 3 Ultra transcatheter heart valve (THV) is associated with substantial reductions in paravalvular leak (PVL) compared to the previous Sapien 3 THV, according to new data published in the American Journal of Cardiology.

Edwards Lifesciences developed the Sapien 3 Ultra THV with PVL in mind. To test this next-generation THV with its predecessor, the Sapien 3 THV, researchers examined data from more than 4,000 patients who participated in one of seven observational studies. Approximately 49% of patients received the Sapien 3 Ultra THV, and the remaining patients received the Sapien 3 THV.

While 52% of TAVR patients were female, the mean patient age was 79.9 years old. The mean Society of Thoracic Surgeons score was 4.4.

Overall, the Sapien 3 Ultra THV was associated with “a significant reduction” in both mild PVL (13.4% vs. 28.4%) and moderate/severe PVL (0.71% vs. 1.71%) when compared to its predecessor. The risk of all-cause mortality, stroke, major bleeding events or permanent pacemaker implantation was similar between the two valves.

The study’s authors believe their work to be the first meta-analysis of its kind.

“Because the current literature suggests a strong association between moderate/severe PVL and adverse outcomes, these important findings require further confirmation in randomized controlled trials that are less susceptible to confounding,” wrote lead author Omar M. Abdelfattah, MD, a specialist with Morristown Medical Center in Morristown, New Jersey, and colleagues. “Further, larger long-term studies are also needed to confirm if the aforementioned hemodynamic improvements translate into better clinical outcomes and long-term hemodynamic durability.”

The full study is available here

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup